Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

Cancer Chemotherapy Regimen for Ovarian Cancer


 IP-CC                                                ovarian(117)
 _________________________________________________________________
  cisplatin....... 200 mg/sqm IP over 30 minutes.
  cytarabine...... 2,000 mg IP over 30 minutes.
  FREQUENCY....... Repeat cycle every 28 days.


  reference...
    Markman M.  Cleary S.  Lucas WE.  Howell SB. Intraperitoneal 
    chemotherapy with high-dose cisplatin and cytosine arabinoside 
    for refractory ovarian carcinoma and other malignancies 
    principally involving the peritoneal cavity. Journal of 
    Clinical Oncology.  3(7):925-31, 1985 Jul. 
  abstract...
    Sixty-two patients with refractory ovarian carcinoma or other 
    malignancies principally confined to the peritoneal cavity 
    were treated with an intraperitoneal combination chemotherapy 
    regimen consisting of cisplatin (100 mg/m2 or 200 mg/m2) and 
    cytosine arabinoside (4 X 10(-3) mol/L or 10(-2) mol/L). 
    Sodium thiosulfate was simultaneously administered 
    intravenously (IV) to protect against cisplatin-induced 
    nephrotoxicity. Sixteen of 52 evaluable patients demonstrated 
    evidence of a clinical response including 14 (36%) of 39 with 
    refractory ovarian carcinoma. Systemic toxicity was not severe 
    except for cisplatin-induced emesis and a single episode of 
    major renal insufficiency. Dose-limiting toxicity was bone 
    marrow suppression with cytosine arabinoside administered at 
    10(-2) mol/L. We conclude that combination intraperitoneal 
    therapy with high-dose cisplatin and cytosine arbinoside can 
    be safely administered with objective tumor responses observed 
    in patients with ovarian carcinoma refractory to front-line 
    chemotherapy and in occassional individuals with other 
    malignancies principally confined to the peritoneal cavity. 
 

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 

 advertisement.gif (61x7 -- 0 bytes)

 

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.